Replies to post #3059 on Sons and Daughters of BBCMF , Dow 30 With Point an

[mick]

Teva Pharm announces The U.S. Court of Appeals has reversed summary judgment in Teva's favor on the issue of non-infringement with regard to PFE's patent (TEVA) 43.27 -0.37 : Co announces that the United States Court of Appeals for the Federal Circuit has reversed and remanded an August 2005 summary judgment decision by the U.S. District Court for the District of New Jersey with regards to Pfizer Inc.'s U.S. Patent No. 6,054,482. The District Court had granted summary judgment in Teva's favor on the issue of non-infringement with regard to the patent, which is otherwise set to expire in 2017. The Court of Appeals affirmed the claim construction, but found that there were facts in dispute that prevented summary judgment and required a trial. The case has been remanded to the District Court for further proceedings, which will involve Teva's allegations of invalidity and non-infringement.